González Borja, IranzuViúdez, AntonioGoñi Irigoyen, SaioaSantamaría Martínez, EnriqueCarrasco García, EstefaníaPérez Sanz, JairoHernández García, Irene2020-02-182020-02-1820192072-669410.3390/cancers11081052https://academica-e.unavarra.es/handle/2454/36276Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.19 p.application/pdfeng© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Pancreatic adenocarcinomaCtDNAProteomicGenomicMetabolomicLipidomicFFPETissueBody fluidsinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess